{"id":382169,"date":"2020-11-16T16:04:27","date_gmt":"2020-11-16T21:04:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382169"},"modified":"2020-11-16T16:04:27","modified_gmt":"2020-11-16T21:04:27","slug":"atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/","title":{"rendered":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences"},"content":{"rendered":"

<\/p>\n

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Atara Biotherapeutics, Inc.<\/a> (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences.\n<\/p>\n

Stifel 2020 Virtual Healthcare Conference
\n
<\/b>Wednesday, November 18, 2020 at 4:40 p.m. EST
\n
Fireside Chat with Pascal Touchon, President and Chief Executive Officer\n<\/p>\n

Evercore ISI 3rd Annual Virtual HealthCONx Conference
\n
<\/b>Wednesday, December 2, 2020 at 8:50 a.m. EST
\n
Fireside Chat with Pascal Touchon and Jakob Dupont, Global Head of Research and Development\n<\/p>\n

\nLive video webcasts of both presentations will be available by visiting the Investor Events and Presentations<\/a> section of atarabio.com<\/a>. Archived replays will be available on the Company’s website for approximately 14 days following the live webcasts.\n<\/p>\n

About Atara Biotherapeutics, Inc.<\/i><\/b><\/p>\n

Atara Biotherapeutics, Inc.<\/a>(@Atarabio)<\/a> is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel\u00ae<\/sup> (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+<\/sup> PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients\u2019 lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. For additional information about the company, please visit atarabio.com<\/a> and follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201116005687\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/i><\/b>
Eric Hyllengren
\n
Vice President, Investor Relations & Finance
\n
Atara Biotherapeutics
\n
805-395-9669
\n
ehyllengren@atarabio.com<\/a><\/p>\n

Media
\n<\/i><\/b>
Kerry Beth Daly
\n
Head, Corporate Communications
\n
Atara Biotherapeutics
\n
516-982-9328
\n
kdaly@atarabio.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Genetics Clinical Trials Stem Cells Biotechnology General Health Pharmaceutical Health Science Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 at 4:40 p.m. EST Fireside Chat with Pascal Touchon, President and Chief Executive Officer Evercore ISI 3rd Annual Virtual HealthCONx Conference Wednesday, December 2, 2020 at 8:50 a.m. EST Fireside Chat with Pascal Touchon and Jakob Dupont, Global Head of Research and Development Live video webcasts of both presentations will be available … <\/p>\n

Continue reading “Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAtara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 at 4:40 p.m. EST Fireside Chat with Pascal Touchon, President and Chief Executive Officer Evercore ISI 3rd Annual Virtual HealthCONx Conference Wednesday, December 2, 2020 at 8:50 a.m. EST Fireside Chat with Pascal Touchon and Jakob Dupont, Global Head of Research and Development Live video webcasts of both presentations will be available … Continue reading "Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T21:04:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences\",\"datePublished\":\"2020-11-16T21:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/\"},\"wordCount\":440,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/\",\"name\":\"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-16T21:04:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk","og_description":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 at 4:40 p.m. EST Fireside Chat with Pascal Touchon, President and Chief Executive Officer Evercore ISI 3rd Annual Virtual HealthCONx Conference Wednesday, December 2, 2020 at 8:50 a.m. EST Fireside Chat with Pascal Touchon and Jakob Dupont, Global Head of Research and Development Live video webcasts of both presentations will be available … Continue reading \"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T21:04:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences","datePublished":"2020-11-16T21:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/"},"wordCount":440,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/","name":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-16T21:04:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201116005687r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/atara-biotherapeutics-to-participate-at-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}